MD Anderson Cancer Center
Internal Medicine
Dr. Lauren A. Byers, MD
|
|
Give Review
Lauren Byers works in the field of Internal Medicine. She went to medical school at Baylor College of Medicine. Lauren A. Byers is a published doctor and has 35 publications published. The lastest was: 'Thermodilution measurement of cardiac output in patients with low output: room-temperature versus iced injectate.' She accepts all Medicare patients.
Publications
- Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in l...
- A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
- Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?
- The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers.
- drexplorer: A tool to explore dose-response relationships and drug-drug interactions.
- Small cell lung cancer: Where do we go from here?
- A HER 1-2 Punch: Dual EGFR Targeting Deals Resistance a Deadly Blow.
- A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma.
- Assessing the clinical utility of cancer genomic and proteomic data across tumor types.
- Management of the lymph node-positive neck in the patient with human papillomavirus-associated oropharyngeal cancer.
- Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer--Response.
- Smoking, p53 mutation, and lung cancer.
- Teaching an old dog new tricks: drug repositioning in small cell lung cancer.
- Progress in the management of limited-stage small cell lung cancer.
- Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
- HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
- An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhi...
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome.
- Increased VEGFR-2 Gene Copy Is Associated With Chemoresistance and Shorter Survival in Patients with Non-small Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy.
- DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy.
- Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence.
- Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.
- Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer.
- Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor r...
- Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung can...
- Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer.
- Blasted cell line names.
- Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters.
- Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.
- Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.
- Thermodilution measurement of cardiac output in patients with low output: room-temperature versus iced injectate.
- Chronic myelogenous leukemia cell growth and maturation in liquid culture.
- A pan-cancer proteomic perspective on The Cancer Genome Atlas.
- Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.
Doctors Specialties
- Internal Medicine
Accepted Insurances
Education
-
Baylor College of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1730245911 | |
| NPPES Provider LastName | BYERS | |
| NPPES Provider FirstName | LAUREN | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 143.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1730245911 |
| Last Name Of The Provider | BYERS |
| First Name Of The Provider | LAUREN |
| View All |
Similar Doctors
|
|
Dr. Hope D. Shipman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonard H. Zalavarria, MD |
|
|
Dr. Kenneth K. Poon, MD |
|
|
Dr. Alexis U. Schmitt, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ghassan Haddad, MD |
|
|
Dr. Marlos R. Fernandes, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Luis G. Granier, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michael L. Warneke, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sanjay R. Pallegar, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Nghia C. Nguyen, MD |